Week Ending April 19, 2021

Ceralasertib/Durvalumab Combination Stands Out in HUDSON Trial for Patients With NSCLC
“For patients non–small cell lung cancer (NSCLC) who previously progressed on chemotherapy and immune checkpoint inhibitors, ceralasertib plus durvalumab (Imfinzi) proved effective compared with patients with the same profile who received durvalumab alone, according to findings from the ongoing HUDSON study.1”

An Overview of EGFR Mutation Lung Cancer
“EGFR stands for epidermal growth factor receptor. It’s a protein found on healthy cells.”

Antibiotics With Keytruda May Affect Survival in Non-Small Cell Lung Cancer
“Antibiotics cause a significant negative impact on patients with non-small cell lung cancer who are being treated with Keytruda (pembrolizumab) alone, although there is not a similar impact on those treated with chemotherapy alone, according to data published in the Journal for ImmunoTherapy of Cancer.”

Immunotherapy Alone Extended Life for Metastatic Lung Cancer Patients with KRAS Mutation
“PHILADELPHIA—Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research from the Abramson Cancer Center at the University of Pennsylvania.”

Types of Lung Cancer Surgery: What to Expect and How to Lower Your Risk for Complications
“Lung cancer is a type of cancer that starts in or spreads to the lungs. Lung cancer is the No. 1 type of cancer that kills both men and women, according to the Centers for Disease Control and Prevention. However, lung cancer that’s detected early enough can be treated and is associated with higher rates of survival.”

A Win for Nivolumab as Preoperative Therapy for Lung Cancer
“Adding the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy dramatically increased pathologic complete response (pCR) in patients with operable lung cancer, a randomized trial showed.”

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent
“DARMSTADT, Germany–(BUSINESS WIRE)–Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company’s DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide.”

Video:
Vivek Subbiah, MD, on Data from AACR on Resistance Mechanisms to KRAS Inhibitors
“CancerNetwork® spoke with Vivek Subbiah, MD, about data regarding mechanisms of resistance to investigational KRAS G12C inhibitors that was presented at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.1 The abstract he spotlighted explored the use of adagrasib and sotorasib in patients with non–small cell lung cancer or colorectal cancer and mutations in KRAS G12C.”

New technology could transform how Northwest doctors diagnose, treat lung cancer
“PORTLAND, Ore — Some revolutionary new technology is transforming how doctors diagnose and treat lung cancer. It’s called the Monarch system. It’s a machines that uses robotics, sensors and data to help physicians detect lung nodules.”

VIDEO: PeaceHealth first hospital in the pacific northwest to offer ION robotic assisted bronchoscopy
“VANCOUVER —PeaceHealth Southwest Medical center in Vancouver brings cutting edge technology to perform minimally invasive lung biopsy: a robot.”